ArticleStatistics in biosciences2016
Subgroup-Based Adaptive (SUBA) Designs for Multi-Arm Biomarker Trials.
Article in Statistics in biosciences, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Pooled it
- The clinical trials landscape for glioblastoma: is it adequate to develop new treatments?Neuro-oncology · 2018Pooled it
- Methods for identification and confirmation of targeted subgroups in clinical trials: A systematic review.Journal of biopharmaceutical statistics · 2016Pooled it
- The Translational Paradox of Cancer Nanomedicine: Biological, Pharmacokinetic, and Manufacturing Barriers to Clinical Success.Biology · 2026Review
- Latest Developments in "Adaptive Enrichment" Clinical Trial Designs in Oncology.Therapeutic innovation & regulatory science · 2024Review
- Improving Seizure Frequency Documentation and Classification.Neurology. Clinical practice · 2023Article
- Bayesian treatment screening and selection using subgroup-specific utilities of response and toxicity.Biometrics · 2023Article
- Innovative trial design in precision oncology.Seminars in cancer biology · 2022Review
- Adaptive Enrichment Designs in Clinical Trials.Annual review of statistics and its application · 2021Article
- A nonparametric Bayesian basket trial design.Biometrical journal. Biometrische Zeitschrift · 2019Article
- Building of EMR Tools to Support Quality and Research in a Memory Disorders Clinic.Frontiers in neurology · 2019Article
- Bayesian Approaches to Subgroup Analysis and Related Adaptive Clinical Trial Designs.JCO precision oncology · 2019Review
- Design and implementation of pragmatic clinical trials using the electronic medical record and an adaptive design.JAMIA open · 2018Article
- Article
- Structured clinical documentation in the electronic medical record to improve quality and to support practice-based research in epilepsy.Epilepsia · 2017Article
- A Bayesian credible subgroups approach to identifying patient subgroups with positive treatment effects.Biometrics · 2016Article
- Quality improvement and practice-based research in neurology using the electronic medical record.Neurology. Clinical practice · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Targeted therapies based on biomarker profiling are becoming a mainstream direction of cancer research and treatment. Depending on the expression of specific prognostic biomarkers, targeted therapies assign different cancer drugs to subgroups of patients even if they are diagnosed with the same type of cancer by traditional means, such as tumor location. For example, Herceptin is only indicated for the subgroup of patients with HER2+ breast cancer, but not other types of breast cancer. However, subgroups like HER2+ breast cancer with effective targeted therapies are rare and most cancer drugs are still being applied to large patient populations that include many patients who might not respond or benefit. Also, the response to targeted agents in humans is usually unpredictable. To address these issues, we propose SUBA, subgroup-based adaptive designs that simultaneously search for prognostic subgroups and allocate patients adaptively to the best subgroup-specific treatments throughout the course of the trial. The main features of SUBA include the continuous reclassification of patient subgroups based on a random partition model and the adaptive allocation of patients to the best treatment arm based on posterior predictive probabilities. We compare the SUBA design with three alternative designs including equal randomization, outcome-adaptive randomization and a design based on a probit regression. In simulation studies we find that SUBA compares favorably against the alternatives.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.